[Treatment of fistulating pouchitis with tumour necrosis factor-alpha-inhibitor (infliximab)].
The surgical first choice treatment for patients with ulcerative colitis (UC) involves total proctocolectomy with ileal pouch-anal anastomosis (IPAA). Postoperative development of pouch-related fistula is a rare complication, but it is associated with significant morbidity, a high recurrence rate and is a major cause of pouch failure. We report the use of infliximab, a monoclonal antibody to tumour necrosis factor-alpha, in three patients who developed pouch-related fistula after undergoing IPAA surgery for UC.
Semb
Synne
S
Gastroenheden, Medicinsk Sektion, afsnit 439, Hvidovre Hospital, DK-2650 Hvidovre. synnesemb@hotmail.com
Nordgaard-Lassen
Inge
I
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001004:Anus Diseases / Q000188:drug therapy / Q000209:etiology; D003093:Colitis, Ulcerative / Q000601:surgery; D039021:Colonic Pouches / Q000009:adverse effects; D005260:Female; D006801:Humans; D000069285:Infliximab; D007412:Intestinal Fistula / Q000188:drug therapy / Q000209:etiology; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy / Q000209:etiology; D019449:Pouchitis / Q000188:drug therapy* / Q000209:etiology; D016737:Proctocolectomy, Restorative / Q000009:adverse effects; D014624:Vaginal Fistula / Q000188:drug therapy / Q000209:etiology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab